GlassScriptPhysician profile
Amy L Luchsinger
NPI 1285067637
$3,068.34
in general payments reported to CMS, 2019-2025
33 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $923 · 2022: $737 · 2023: $579 · 2024: $450 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.73 | 2021-2024 | |
| Amgen INC. | $341.68 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $248.65 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $178.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $171.87 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $145.26 | 2021-2024 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $121.21 | 2022 | |
| Almatica Pharma LLC | $119.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.32 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $97.08 | 2022-2024 | |
| Pfizer INC. | $95.76 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.34 | 2021-2023 | |
| Astellas Pharma US INC | $79.27 | 2022-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $78.24 | 2022-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $76.36 | 2021-2025 | Verquvo, Belsomra, Steglatro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.03 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $59.49 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $58.25 | 2023-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $43.62 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $41.06 | 2024-2025 | Rexulti |
| Ucb, INC. | $38.96 | 2022-2024 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $38.10 | 2021-2022 | |
| Shield Therapeutics INC | $36.95 | 2023-2024 | Accrufer |
| Boston Scientific Corporation | $34.69 | 2025 | Watchman |
| Arbor Pharmaceuticals, INC. | $30.55 | 2021 | |
| Exact Sciences Corporation | $30.30 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $23.36 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.53 | 2025 | Voquezna |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $21.42 | 2021 | |
| Insulet Corporation | $15.37 | 2025 | Omnipod |
| Corium, LLC | $13.46 | 2023 | Azstarys |
| Esperion Therapeutics, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Luchsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.